Apaziquone for non-muscle invasive bladder cancer: a critical review
| Autor: | J. Alfred Witjes, Prasad S Kolli |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
medicine.medical_specialty Aziridines Drug Evaluation Preclinical Urology MEDLINE Aetiology screening and detection [ONCOL 5] Molecular epidemiology [NCEBP 1] chemistry.chemical_compound Translational research [ONCOL 3] Interventional oncology [UMCN 1.5] Internal medicine Epidemiology medicine Animals Humans Pharmacology (medical) Apaziquone Indolequinones Pharmacology Muscle Neoplasms Bladder cancer Hereditary cancer and cancer-related syndromes [ONCOL 1] business.industry Drug Tolerance General Medicine medicine.disease Clinical Practice Urinary Bladder Neoplasms chemistry Non muscle invasive business |
| Zdroj: | Expert Opinion on Investigational Drugs, 17, 7, pp. 1085-96 Expert Opinion on Investigational Drugs, 17, 1085-96 |
| ISSN: | 1744-7658 1354-3784 |
| Popis: | Item does not contain fulltext OBJECTIVE: To describe clinical needs in non-muscle invasive bladder cancer (NMIBC) and review the potential of apaziquone in this respect. METHODS: Epidemiology and clinical practice in NMIBC, as well as new drugs and strategies are reviewed. RESULTS: Bladder cancer is a heterogeneous and frequent disease. Clinical risk factors help in determining additional therapy after initial resection. However, current treatments have clear limitations with regard to efficacy and/or toxicity. New drugs and strategies have been tested recently and are in (pre)clinical use. Intravesical apaziquone (EOquin) is a new drug. It has theoretical advantages for intravesical use, has proven safety and is presently under further clinical evaluation. CONCLUSION: Apaziquone is a promising drug for intravesical use in patients with NMIBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|